We Are Hologic

As a leading global healthcare and diagnostics company, we strive to make advances toward greater certainty for our customers by providing them with cutting-edge technology that makes a real difference. We move to narrow the gap between doubt and confidence and work to achieve both incremental and transformational progress to improve patients’ lives.

We are passionate and resolute in our purpose; we call it The Science of Sure. This ethos is extended throughout our core offerings: Breast & Skeletal Health, Diagnostic, and GYN Surgical Solutions. We believe it is our responsibility to offer our customers ever-greater certainty – what we call progressive certainty – by pushing the boundaries of science.

We act with integrity. We innovate with determination. We are Hologic.

Events

Events not available

News

IMAGING Management

Hologic selected for Dutch Breast Cancer Screening Program

2017 02 Nov

Under the tender, state-of-the-art 3DimensionsTM mammography systems will be installed starting in 2018   Hologic, Inc. (Nasdaq: HOLX) has announced that it will provide all mammography systems for the Dutch Breast Cancer Screening Program in partnership with Tromp Medical, Hologic’s distributor in the Netherlands. Under the tender, Hologic’s new, state-of-the-art... Read more

IMAGING Management

2017 30 Oct

Expanding leadership based on clinical evidence In early September, Hologic launched the new 3Dimensions™ mammography system, a breast tomosynthesis system with the fastest and highest resolution, in EMEA. I recently had the pleasure of showcasing this cutting-edge device at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting,... Read more

IMAGING Management

Paraflu Assay Now FDA Cleared on Hologic's New Panther Fusion® System

2017 26 Oct

-- New Assay Extends Respiratory Testing Menu; Modular Panels and Fusion System Increase Efficiency and Flexibility for the Laboratory –   Hologic, Inc. (Nasdaq: HOLX) announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Panther Fusion® Paraflu assay, a multiplexed assay which runs on the... Read more

IMAGING Management

Hologic Receives CE Mark to Market SculpSure® for Non-Invasive Body Contouring of the Submental Area

2017 19 Oct

Patients in Clinical Studies Report 100% Satisfaction Hologic, Inc. (Nasdaq: HOLX) has announced that it has received an additional European Medical Device Directive (MDD) certification for SculpSure®, a state-of-the-art body contouring laser treatment. The device is now certified to treat a double chin (also known as the submental area), marking the... Read more

IMAGING Management

Panther Fusion® Flu A/B/RSV Assay Now FDA Cleared on Hologic's New Panther Fusion® System

2017 06 Oct

- New Panther Fusion Module Expands System's Molecular Testing Capabilities, Increases Efficiency and Flexibility for the Laboratory   Hologic, Inc. (Nasdaq: HOLX) has announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Panther Fusion® Flu A/B/RSV assay running on the new Panther Fusion®... Read more

IMAGING Management

Hologic enters into amended and restated five-year secured credit agreement

2017 04 Oct

- Initial Proceeds from New $1.5 Billion Term Loan and $1.5 Billion Revolving Credit Line Used to Refinance Senior Secured Debt -- Funds Also Expected to Contribute to Retirement of Remaining Convertible Notes -Hologic, Inc. (NASDAQ: HOLX) has announced  that the Company has entered into an amended and restated credit agreement consisting of a new,... Read more

IMAGING Management

Hologic announces offering of $350 Million of Senior Notes due 2025

2017 04 Oct

- Proceeds Expected to Contribute to Retirement of Remaining Convertible Notes -Hologic, Inc. (NASDAQ: HOLX) has announced that it has launched, subject to market and other conditions, a private offering of $350 million aggregate principal amount of senior notes due 2025.  Hologic intends to use the proceeds of the offering and available cash, including... Read more

IMAGING Management

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2017

2017 03 Oct

Hologic, Inc. (Nasdaq: HOLX) has announced that the Company plans to release its financial results for the fourth quarter of fiscal 2017 on Wednesday, November 8, 2017 after the market closes.  In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.   Interested participants may listen to the call... Read more

IMAGING Management

Hologic CEO Steve MacMillan to Ring Nasdaq Opening Bell to Kick Off Breast Cancer Awareness Month

2017 30 Sep

Trailblazing Company Behind the Genius™ 3D Mammography™ Exam Celebrates Year of Innovations in Breast Health Hologic, Inc. (Nasdaq: HOLX) has announced that Steve MacMillan, the Company's Chairman, President and Chief Executive Officer, will join selected employees to ring the Nasdaq Opening Bell on October 2 in conjunction with the start of Breast... Read more

IMAGING Management

Hologic receives FDA 510(k) clearance to market SculpSure® for non-invasive body contouring

2017 30 Sep

Patients in Clinical Studies Report 100% Satisfaction Rate   Hologic, Inc. (Nasdaq: HOLX) has announced that the U.S. Food and Drug Administration (FDA) has granted an expanded FDA 510(k) clearance for Cynosure's non-invasive body contouring product, SculpSure®. The state-of-the-art body contouring laser treatment is now cleared to treat a double chin... Read more

IMAGING Management

Hologic introduces a more comfortable mammogram

2017 27 Sep

93% of Women Surveyed Reported Improved Comfort with the New System*Hologic, Inc. (Nasdaq: HOLX) has announced the commercial availability of its new SmartCurve™ breast stabilization system, which has been clinically proven to deliver a more comfortable mammogram without compromising image quality, workflow or dose.1 The SmartCurve system is available... Read more

IMAGING Management

New USPSTF draft Cervical Cancer Screening recommendations are a step back for Women's Health

2017 16 Sep

Hologic, Inc. (Nasdaq: HOLX) is deeply concerned that the United States Preventive Services Task Force (USPSTF) did not include a grade for co-testing (also known as Pap+HPV Together) in draft cervical cancer screening recommendations released this week. These draft recommendations do not consider the wealth of data supporting the value of co-testing,... Read more

IMAGING Management

Hologic’s 3Dimensions™ Mammography System now available in Europe

2017 12 Sep

Fastest, Highest Resolution Breast Tomosynthesis System is Designed to Increase Clinical Confidence, Accuracy and Patient ComfortHologic, Inc. (Nasdaq: HOLX) has announced that the 3Dimensions™ mammography system, the fastest, highest resolution breast tomosynthesis system ever, is available for purchase in Europe.[1] The new product is the latest addition... Read more

IMAGING Management

Hologic Announces Availability of New Brevera® Breast Biopsy System

2017 31 Aug

Transformational Workflow Solution Offers Real-Time Imaging of Tissue Samples, Resulting in Major Cost and Time SavingsHologic, Inc. (Nasdaq: HOLX) has announced U.S. commercial availability of the Brevera® breast biopsy system with CorLumina®imaging technology, a groundbreaking real-time breast biopsy and verification system that enhances workflow,... Read more

IMAGING Management

Hologic Announces Financial Results for Third Quarter of Fiscal 2017

2017 03 Aug

-- Company Posts Revenue of $806.1 Million, GAAP Diluted EPS of $0.21, and Non-GAAP Diluted EPS of $0.50 ---- Organic Revenue Growth Led by Molecular Diagnostics and International Businesses --Hologic, Inc. (Nasdaq: HOLX) has announced the Company's financial results for the fiscal third quarter ended July 1, 2017.  GAAP diluted earnings per share (EPS)... Read more

IMAGING Management

Hologic to Webcast Presentations at Upcoming Investor Conferences

2017 31 Jul

 Hologic, Inc. (Nasdaq: HOLX) has announced that the Company will present at these upcoming investor conferences:The Canaccord Genuity Growth Conference in Boston, MA on Wednesday, August 9 at 4 p.m. Eastern Time (ET).Morgan Stanley's 15th Annual Global Healthcare Conference in New York, NY on Monday, September 11 at 9:55 a.m. ET.Each presenta Read more

IMAGING Management

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2017 on Wed, August 2, 2017

2017 12 Jul

Hologic, Inc. (Nasdaq: HOLX) has announced that the Company plans to release its financial results for the third quarter of fiscal 2017 on Wednesday, August 2, 2017, after the market closes.  In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.Interested participants may listen to the call by dialing... Read more

IMAGING Management

Hologic Notified Holders of 2.00% Convertible Exchange Senior Notes Due 2042 are Eligible to Convert

2017 03 Jul

Hologic, Inc. (Nasdaq: HOLX) has announced that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2042 (CUSIP No. 436440 AC5) issued March 5, 2012, and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes.  This conversion right is subject to the... Read more

IMAGING Management

Hologic's New Panther Fusion® System, Flu and Respiratory Assays Now CE Marked in Europe

2017 29 Jun

New Panther Fusion® Module Expands Molecular Testing Capabilities, Increases Productivity and Flexibility for the LaboratoryHologic, Inc. (Nasdaq: HOLX) has obtained a CE mark in Europe for its new Panther Fusion system and Panther Fusion assays for flu and respiratory testing, the Company has announced. The Fusion module system offers laboratories... Read more

IMAGING Management

Hologic Announces FDA Clearance of Aptima® Assay to Detect Herpes Simplex Virus 1 & 2

2017 21 Jun

Hologic, Inc. (Nasdaq: HOLX) has announced  that it has obtained FDA clearance to market the Aptima® Herpes Simplex Virus (HSV) 1 & 2 molecular assay on the fully automated Panther® system. The test will be commercially available in the 50 United States, U.S. territories and Puerto Rico. According to the U.S. Centers for Disease Control and Prevention,... Read more

IMAGING Management

Hologic Receives Expanded FDA 510(k) Clearance to Market Cynosure's SculpSure®

2017 16 Jun

SculpSure Now Cleared to Treat Five Areas of the BodyHologic, Inc. (Nasdaq: HOLX) has announced that the U.S. Food and Drug Administration (FDA) has granted an expanded clearance for Cynosure's non-invasive body contouring product, SculpSure, to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of... Read more

IMAGING Management

FDA Approves Hologic's Genius™ 3D Mammography™ Exam

2017 08 Jun

--Genius exam improves cancer detection and reduces recall rates for women of all ages and breast types, including the nearly 50 percent of women of breast cancer screening age who have dense breasts----Separate, recently published data analysis strongly supports starting breast cancer screening using tomosynthesis beginning at age 40--Hologic, Inc.... Read more

IMAGING Management

Charles J. Dockendorff Elected to Hologic Board of Directors

2017 17 May

Hologic, Inc. (Nasdaq: HOLX) has announced that Charles J. Dockendorff has been elected to the Company's Board of Directors, effective immediately.  Mr. Dockendorff also was appointed to the Company's Audit and Finance Committee.Mr. Dockendorff, who has more than 25 years of experience in the global healthcare industry, was formerly the Executive Vice... Read more

IMAGING Management

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2017 on May 10, 2017

2017 04 Apr

Hologic, Inc. (Nasdaq: HOLX) has announced that the Company plans to release its financial results for the second quarter of fiscal 2017 on Wednesday, May 10, 2017, after the market closes.  In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.Interested participants may listen to the call by dialing... Read more

IMAGING Management

Hologic Completes Acquisition of Cynosure

2017 22 Mar

- Transaction Provides Entry into Large, Fast-Growing Medical Aesthetics Market, Boosts Hologic's Growth Rate -Hologic, Inc. (Nasdaq: HOLX) has announced  that it has completed the acquisition of Cynosure, Inc., a leader in medical aesthetics systems and technologies, for $66 per share in cash."We are pleased to complete our acquisition of Cynosure,... Read more

IMAGING Management

FDA Grants PMA Approval for Hologic's Aptima® Hepatitis C Quant Dx Assay

2017 18 Feb

HCV viral load test now available alongside HIV-1 assay and women's health menu on the fully automated Panther systemHologic, Inc. (Nasdaq: HOLX) has announced that the United States Food and Drug Administration (FDA) has granted PMA approval for the Company's hepatitis C virus (HCV) assay for quantitation of HCV viral load and confirming active HCV... Read more

IMAGING Management

Hologic to Acquire Cynosure,in All-Cash Tender Offer that Combines Two Complementary Businesses

2017 14 Feb

-Expands Hologic's Scientific and Commercial Expertise into Large, Adjacent Medical Device Segment Growing at Double-Digit Rate -Accelerates Hologic's Top- and Bottom-Line Growth Rates and is Immediately Accretive to Non-GAAP Earnings per Share \Hologic, Inc. (Nasdaq: HOLX), a leader in women's health, and Cynosure, Inc. (Nasdaq: CYNO), a leader in... Read more

IMAGING Management

Hologic to Webcast Presentations at Upcoming Investor Conferences

2017 13 Feb

Hologic, Inc. (Nasdaq: HOLX) has announced that the Company will present at these upcoming investor conferences:The LEERINK Partners 6th Annual Global Healthcare Conference in New York, NY on Wednesday, February 15 at 3:30 pm Eastern Time (ET).The Raymond James 38th Annual Institutional Investor Conference in Orlando, FL on Monday, March 6 at& Read more

IMAGING Management

Hologic Launches Next-Generation NovaSure® ADVANCED Global Endometrial Ablation System

2017 03 Feb

--Smaller 6 mm Diameter and Product Updates Are Designed to Enhance Patient Comfort and Improve Physician Ease-of-Use--Hologic, Inc. (Nasdaq: HOLX) has announced the launch of its next-generation NovaSure® ADVANCED global endometrial ablation (GEA) system in the United States. The system has been FDA approved.The NovaSure system is designed to reduce... Read more

IMAGING Management

Hologic Completes Divestiture of Blood Screening Business

2017 02 Feb

- Strengthens Efforts to Build a Sustainable Growth Company -- Accelerates Top- and Bottom-Line Growth Rates, Increases Financial Flexibility -Hologic, Inc. (Nasdaq: HOLX) has completed the divestiture of its blood screening business to long-time commercial partner, Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) for a purchase price of $1.85 billion in... Read more

IMAGING Management

Hologic Appoints President of EMEA and Canada, Completing International Leadership Team

2017 09 Jan

Hologic, Inc. (Nasdaq: HOLX) has announced that Jan Verstreken has been named Regional President for Europe, Middle East and Africa (EMEA) and Canada.  Mr. Verstreken's appointment completes Hologic's international sales leadership team, which includes Sanjay Prabhakaran, Regional President for Asia Pacific, and Fernando Davico, General Manager for... Read more

IMAGING Management

FDA Grants PMA Approval for Hologic's Aptima® HIV-1 Quant Assay

2017 03 Jan

--High-performing HIV viral load test now available alongside broad women's health menu on the fully automated Panther® system--Hologic, Inc. (Nasdaq: HOLX) has announced that the U.S. Food and Drug Administration (FDA) has granted PMA approval for the Company's HIV-1 viral load monitoring assay. The Aptima® HIV-1 Quant assay is a nucleic acid amplification... Read more

IMAGING Management

Hologic to Showcase Award-Winning Breast Screening and Interventional Solutions at RSNA

2016 27 Nov

--New products spotlight Hologic's leading tomosynthesis technology, including the world's first dedicated prone biopsy system with 2D or 3D™ imaging--Hologic, Inc. (Nasdaq: HOLX) will highlight its portfolio of innovative, award-winning breast cancer screening and interventional products, including the new Affirm™ prone breast biopsy system, at the... Read more

IMAGING Management

First Reviews of New Hologic Affirm™ Prone Biopsy System are Very Positive

2016 06 Nov

Breast tomosynthesis exams, Hologic calls the exams 3D MAMMOGRAPHY, have shown to be an advance over digital mammography, with higher cancer detection rates and fewer patient recalls for additional testing   The new Affirm prone system, which was installed for the first time in Europe earlier this year, is widely considered one the most significant... Read more

IMAGING Management

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2016

2016 03 Nov

- GAAP Diluted EPS of $0.33 Increases 266.7%, Non-GAAP Diluted EPS of $0.52 Increases 20.9% -- Revenue of $726.8 Million Grows 3.4%, 3.8% in Constant Currency -- In Fiscal 2017, Company Expects Mid-Single-Digit Revenue Growth, EPS Growth Roughly Double this Rate -Hologic, Inc. (Nasdaq: HOLX) has announced the Company's financial results for the fiscal... Read more

IMAGING Management

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2016 on November 2, 2016

2016 04 Oct

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2016 on Wednesday, November 2, 2016, after the market closes.  In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.Interested participants may listen to the call... Read more

IMAGING Management

Hologic Notice that Holders of 2% Convertible Exchange Senior Notes Due 2037 are Eligible to Convert

2016 04 Oct

Hologic, Inc. (Nasdaq: HOLX) has announced that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. 436440 AB7) issued November 23, 2010, and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes. This conversion right is subject to... Read more

IMAGING Management

Hologic CEO Steve MacMillan & Sheryl Crow Will Be Ringing the Nasdaq Opening Bell on October 3

2016 30 Sep

Hologic, Inc. (Nasdaq: HOLX) has announced that breast cancer survivor and Grammy Award-winner Sheryl Crow will join Steve MacMillan, the Company's Chairman, President and Chief Executive Officer, to ring the Nasdaq Opening Bell on October 3, in conjunction with the start of Breast Cancer Awareness Month.Hologic's participation in the bell ringing marks... Read more

IMAGING Management

FDA Expands Use Authorization for Hologic's Aptima® Zika Virus Assay to Use with Urine Sample

2016 09 Sep

Hologic, Inc. (Nasdaq: HOLX) has announced  that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for the company's Aptima® Zika virus diagnostic assay to be used with urine samples (collected alongside patient-matched serum or plasma specimens).Hologic's Zika virus assay was authorized for emergency use... Read more

IMAGING Management

NCCN Includes Breast Tomosynthesis in Breast Cancer Screening & Diagnosis Practice Guidelines

2016 01 Aug

Hologic Applauds NCCN for Recognizing the Comprehensive Body of Literature Supporting the Use of 3D MAMMOGRAPHY™ Exams for Breast Cancer ScreeningHologic Inc. (Nasdaq: HOLX) has announced that new guidelines published by the National Comprehensive Cancer Network (NCCN) recommend that physicians consider breast tomosynthesis exams as an option for their... Read more

IMAGING Management

Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037

2016 05 Jul

Hologic, Inc. (Nasdaq: HOLX) has announced that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. 436440 AB7) issued November 23, 2010, and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes.  This conversion right is subject... Read more

IMAGING Management

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2016 on July 27, 2016

2016 01 Jul

Hologic, Inc. (Nasdaq: HOLX) has announced that the Company plans to release its financial results for the third quarter of fiscal 2016 on Wednesday, July 27, 2016, after the market closes.  In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.Interested participants may listen to the call by dialing... Read more

Executive Health Management

FDA Approves Use of the Procleix Zika Virus Assay from Hologic & Grifols

2016 21 Jun

--Blood banks will use the new test, co-developed by Hologic and Grifols, to screen donated blood in potential endemic areas of the US----Test will run on the Procleix Panther System, a fully automated NAT blood screening platform--Hologic, Inc. (NASDAQ: HOLX) and Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) – market-leading partners committed to... Read more

IMAGING Management

FDA Grants Emergency Use Authorization for Hologic's Aptima® Zika Virus Assay

2016 20 Jun

New Diagnostic Test for the Detection of the Zika Virus Now Available for Use on Fully Automated Panther SystemHologic, Inc. (Nasdaq: HOLX) has announced that the U.S. Food and Drug Administration (FDA) granted emergency use authorization for the company's new, diagnostic assay for Zika virus infection. The Aptima® Zika Virus assay is a molecular diagnostic... Read more

IMAGING Management

KLAS Report Shows Hologic Continuing to Lead the U.S. Breast Tomosynthesis Market

2016 15 Jun

Mammography customers highlight Hologic's high image quality, strong customer support, and market-leading product innovationsHologic (NASDAQ: HOLX) has announced that the Company received top marks from U.S. mammography providers in a new independent report from KLAS Research, with 96 percent of customers reporting that Hologic systems are worth the... Read more

IMAGING Management

Sheryl Crow is Hologic's National Celebrity Spokesperson for New Breast Cancer Educational Campaign

2016 02 Jun

Award-winning performer and breast cancer survivor to educate women about early detection and the Genius™ 3D MAMMOGRAPHY™ examHologic, Inc. (NASDAQ: HOLX) has announced that nine-time Grammy award-winning singer, songwriter and breast cancer survivor Sheryl Crow will serve as national spokesperson to educate women about a more accurate mammogram, the... Read more

IMAGING Management

Hologic MyoSure® REACH Device Help Physicians Access the Upper Third of the Uterine Cavity

2016 11 May

Company Also Will Feature Full Range of Women's Health Topics at 2016 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific MeetingHologic, Inc. (Nasdaq: HOLX) has announced that the MyoSure® suite of gynecologic surgical products is expanding to include the MyoSure REACH device. The MyoSure REACH device confronts... Read more

IMAGING Management

Study Supports Screening with Pap+HPV Together™ as Best Way to Detect Cervical Cancer & Pre-Cancer

2016 03 May

Co-testing with Pap+HPV Together™ results in significantly fewer false-negative results than either test used alone 1A new cervical cancer screening study demonstrates that Pap+HPV Together™ (co-testing) remains the most effective strategy for detecting high-grade cervical lesions1,2, Hologic, Inc. (Nasdaq: HOLX) has announced. The study, published... Read more

IMAGING Management

Hologic Marks National Osteoporosis Month by Releasing New Consumer Survey

2016 02 May

New Data Suggests Nearly Half of Women Neglect to Take Action Against OsteoporosisWhile nearly three-quarters of Americans (71%) are aware of the effects that osteoporosis can have on their health, only about half report taking any steps to prevent it,1 according to the results of a new survey has announced by Hologic (Nasdaq: HOLX). To mark the start... Read more

IMAGING Management

Hologic Announces Financial Results for Second Quarter of Fiscal 2016

2016 28 Apr

- GAAP Diluted EPS of $0.24 Increases 41.2%, Non-GAAP Diluted EPS of $0.47 Increases 14.6% -- Revenue of $693.3 Million Grows 5.8% on a Reported Basis, 6.3% in Constant Currency -- Company Redeploys $460.2 Million of Capital to Reduce Convertible Debt, and Repurchase Shares -Hologic, Inc. (Nasdaq: HOLX) has announced the Company's financial results... Read more

IMAGING Management

JAMA Conclude that 3D MAMMOGRAPHY™ Exams Outperform Conventional Mammography

2016 27 Apr

Reducing Recall Rate for Breast Cancer Screening Stands to Decrease Healthcare Costs and Increase Quality of Care for WomenHologic, Inc. (Nasdaq: HOLX) has announced that study results published today in a research letter in JAMA conclude that breast tomosynthesis (Hologic's Genius™ 3D MAMMOGRAPHY™) exams reduce recall rates, and increase invasive cancer... Read more

IMAGING Management

Hologic Announces FDA Clearance and Commercial Availability of the Affirm™ Prone Biopsy System

2016 21 Apr

New System Pairs 360-Degree Breast Access with Exceptional 2D/3D™ Biopsy ImagingHologic, Inc. (Nasdaq: HOLX) has announced the U.S. Food and Drug Administration (FDA) clearance and commercial launch of the Affirm™ prone biopsy system, the first dedicated prone biopsy system to offer both 2D and 3D™ imaging-guided breast biopsies."At Hologic, we challenge... Read more

IMAGING Management

Hologic Symposium: High Volume Screening

2016 15 Feb

Several locations have started high volume screening with Hologic 3D Mammography™ in Europe. A large scale adoption is ongoing in the USA with some locations past their third screening round with Hologic 3D Mammography. Results from the use of this technology in screening are concordant and very positive around an increase in invasive cancer detection... Read more

IMAGING Management

Hologic 3D Mammography Workshop: Advanced Case Review

2016 15 Feb

Hologic is offering a series of 90-minute educational sessions for radiologists throughout the ECR Congress. Prior to the hands-on, a brief lecture will be provided by a radiologist pioneer in the clinical use of 3D Mammography™, who will present an overview of the technology and reading principles of tomosynthesis. This program is intended for radiologists... Read more

IMAGING Management

Hologic Innovation Workshop: Breast Biopsy

2016 15 Feb

Hologic is offering a series of 45-minute educational sessions for radiologists. A brief lecture will provide an overview of the clinical experiences with vacuum breast biopsies guided by 3D Imaging, prior to a demonstration of a phantom procedure using live imaging supervised by radiation protection services. This program is intended for radiologists... Read more

IMAGING Management

Hologic Innovation Workshop: Advanced Densitometry

2016 15 Feb

Hologic is offering a series of 45-minutes educational sessions for radiologists. A brief lecture will provide an overview of the clinical experiences of imaging and new quantification applications of DXA. This program is intended for radiologists interested in learning more about new application based on the Hologic DXA technology. Date WS n° Time 04/03/2016 HOL... Read more

IMAGING Management

Hologic Delivers Notice that Holders of 2.00% Converts Due 2037 are Eligible to Convert

2016 05 Jan

Hologic, Inc. (Nasdaq: HOLX) has announced that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 (CUSIP No. 436440 AB7) issued November 23, 2010, and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes.  This conversion right is subject... Read more

Jobs not available

Catalogue

    Catalogue not available

The Corporate Village, Building Caprese, 8th floor, Da Vincilaan 5
Zaventem
1935
Belgium
+32 2 711 46 80

White Papers - Case Studies

Not available

Videos

Articles

Not available